Meta-analysis of various tki generations efficacy either alone or in combinations in EGFR mutated NSCLC

Background. Multiple options of first line treatment in patients with EGFR mutated NSCLC are registered worldwide and, in particular, in Russia. The individual choice for every patient is still based primarily on personal preference of a particular physician and financial possibilities of the region, since no stratification factors are available. At the same time large randomized trials comparing various options are hardly possible in this narrow biomarker restricted population. The additional information on advantages in particular subgroups obtained via indirect comparison might be an important argument.

Materials and methods. We conducted meta‑analysis of trials studying various approaches in first line EGFR mutated NSCLC cancer.

Results. Our meta‑analysis revealed unequal influence of different treatment approaches on OS according to clinical stratification factors. In females (HR 0.79, 95 % CI 0.63–0.99; p = 0.04), patients younger than 65 y. o. (HR 0.66, 95 % CI 0.52–0.83; p = 0.0004), with exon 21 mutations (HR 0.76, 95 % CI 0.59–0.99; p = 0.04) and ECOG 1 (HR 0.72, 95 % CI 0.59–0.89; p = 0.002) OS benefit can be achieved with 2nd generation TKI. In the rest of patients (males, ECOG 0, ex19 deletions) increase in OS necessitates more aggressive treatment with TKI and chemotherapy combination (HR 0.57, 95 % CI 0.41–0.79; p = 0.0008). No influence on OS was observed for TKI and angiogenesis inhibitors. Interestingly, the observed advantage in OS and PFS was not accompanied by response that did not differ between regimens (OR 1.55, 95 % CI 0.86–2.80; p = 0.14).

Conclusions. We showed the importance of individualized approach in the first line EGFR mutated NSCLC selection. Our results underline the need for the new data on various approaches comparison.

1. Cheng Y., Murakami H., Yang P. C., He J., Nakagawa K., Kang J. H., Kim J. H., Wang X., Enatsu S., Puri T., Orlando M., Yang J. C. H. Randomized Phase II Trial of Gefitinib With and Without Pemetrexed as First Line Therapy in Patients With Advanced Nonsquamous Non–Small Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations // Journal of Clinical Oncology. — 2016. — T. 34, № 27. — C. 3258 3266.

2. Han B., Jin B., Chu T., Niu Y., Dong Y., Xu J., Gu A., Zhong H., Wang H., Zhang X., Shi C., Zhang Y., Zhang W., Lou Y., Zhu L., Pei J. Combination of chemotherapy and gefitinib as first line treatment for patients with advanced lung adenocarcinoma and sensitive EGFR mutations: A randomized controlled trial // Int J Cancer. — 2017. — Sep 15. — T. 141, № 6. — C. 1249 1256.

3. Hochmair M. J., Morabito A., Hao D., Yang C. T., Soo R. A., Yang J. C., Gucalp R., Halmos B., Wang L., Marten A., Cufer T. Sequential afatinib and osimertinib in patients with EGFR mutation positive non small cell lung cancer: updated analysis of the observational GioTag study // Future Oncol. — 2019. — Sep. — T. 15, № 25. — C. 2905 2914.

4. Hosomi Y., Morita S., Sugawara S., Kato T., Fukuhara T., Gemma A., Takahashi K., Fujita Y., Harada T., Minato K., Takamura K., Hagiwara K., Kobayashi K., Nukiwa T., Inoue A., North East Japan Study G. Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non Small Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study // J Clin Oncol. — 2020. — Jan 10. — T. 38, № 2. — C. 115 123.

5. Maemondo M., Fukuhara T., Saito H., Furuya N., Watanabe K., Sugawara S., Iwasawa S., Tsunezuka Y., Yamaguchi O., Okada M., Yoshimori K., Nakachi I., Gemma A., Azuma K., Hagiwara K., Nukiwa T., Morita S., Kobayashi K., Group N. E. J. S. NEJ026: Final overall survival analysis of bevacizumab plus erlotinib treatment for NSCLC patients harboring activating EGFR mutations // Journal of Clinical Oncology. — 2020. — T. 38, № 15_suppl. — C. 9506 9506.

6. Mok T. S., Cheng Y., Zhou X., Lee K. H., Nakagawa K., Niho S., Lee M., Linke R., Rosell R., Corral J., Migliorino M. R., Pluzanski A., Sbar E. I., Wang T., White J. L., Wu Y. L. Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non Small Cell Lung Cancer and EGFR Activating Mutations // J Clin Oncol. — 2018. — Aug 1. — T. 36, № 22. — C. 2244 2250.

7. Nakagawa K., Garon E. B., Seto T., Nishio M., Ponce Aix S., Paz Ares L., Chiu C. H., Park K., Novello S., Nadal E., Imamura F., Yoh K., Shih J. Y., Au K. H., Moro Sibilot D., Enatsu S., Zimmermann A., Frimodt Moller B., Visseren Grul C., Reck M., Investigators R. S. Ramucirumab plus erlotinib in patients with untreated, EGFR mutated, advanced non small cell lung cancer (RELAY): a randomised, double blind, placebo controlled, phase 3 trial // Lancet Oncol. — 2019. — Dec. — T. 20, № 12. — C. 1655 1669.

8. Noronha V., Joshi A., Patil V. M., Chougule A., Mahajan A., Janu A., Purandare N., Kumar R., More S., Goud S., Kadam N., Daware N., Shah S., Yadav A., Dutt A., Trivedi V., Behel V., Banavali S. D., Prabhash K. Phase III randomized trial comparing gefitinib to gefitinib with pemetrexed carboplatin chemotherapy in patients with advanced untreated EGFR mutant non small cell lung cancer (gef vs gef+C) // Journal of Clinical Oncology. — 2019. — T. 37, № 15_suppl. — C. 9001 9001.

9. Paz Ares L., Tan E. H., O’Byrne K., Zhang L., Hirsh V., Boyer M., Yang J. C., Mok T., Lee K. H., Lu S., Shi Y., Lee D. H., Laskin J., Kim D. W., Laurie S. A., Kolbeck K., Fan J., Dodd N., Marten A., Park K. Afatinib versus gefitinib in patients with EGFR mutation positive advanced non small cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial // Ann Oncol. — 2017. — Feb 1. — T. 28, № 2. — C. 270 277.

10. Ramalingam S. S., Vansteenkiste J., Planchard D., Cho B. C., Gray J. E., Ohe Y., Zhou C., Reungwetwattana T., Cheng Y., Chewaskulyong B., Shah R., Cobo M., Lee K. H., Cheema P., Tiseo M., John T., Lin M. C., Imamura F., Kurata T., Todd A., Hodge R., Saggese M., Rukazenkov Y., Soria J. C., Investigators F. Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC // N Engl J Med. — 2020. — Jan 2. — T. 382, № 1. — C. 41 50.

11. Saito H., Fukuhara T., Furuya N., Watanabe K., Sugawara S., Iwasawa S., Tsunezuka Y., Yamaguchi O., Okada M., Yoshimori K., Nakachi I., Gemma A., Azuma K., Kurimoto F., Tsubata Y., Fujita Y., Nagashima H., Asai G., Watanabe S., Miyazaki M., Hagiwara K., Nukiwa T., Morita S., Kobayashi K., Maemondo M. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR positive advanced non squamous non small cell lung cancer (NEJ026): interim analysis of an open label, randomised, multicentre, phase 3 trial // Lancet Oncol. — 2019. — May. — T. 20, № 5. — C. 625 635.

12. Seto T., Kato T., Nishio M., Goto K., Atagi S., Hosomi Y., Yamamoto N., Hida T., Maemondo M., Nakagawa K., Nagase S., Okamoto I., Yamanaka T., Tajima K., Harada R., Fukuoka M., Yamamoto N. Erlotinib alone or with bevacizumab as first line therapy in patients with advanced non squamous non small cell lung cancer harbouring EGFR mutations (JO25567): an open label, randomised, multicentre, phase 2 study // Lancet Oncol. — 2014. — Oct. — T. 15, № 11. — C. 1236 44.

13. Wu Y. L., Cheng Y., Zhou X., Lee K. H., Nakagawa K., Niho S., Tsuji F., Linke R., Rosell R., Corral J., Migliorino M. R., Pluzanski A., Sbar E. I., Wang T., White J. L., Nadanaciva S., Sandin R., Mok T. S. Dacomitinib versus gefitinib as first line treatment for patients with EGFR mutation positive non small cell lung cancer (ARCHER 1050): a randomised, open label, phase 3 trial // Lancet Oncol. — 2017. — Nov. — T. 18, № 11. — C. 1454 1466.

14. Yang J. C., Cheng Y., Murakami H., Yang P. C., He J., Nakagawa K., Kang J. H., Kim J. H., Hozak R. R., Nguyen T. S., Zhang W. L., Enatsu S., Puri T., Orlando M. A Randomized Phase 2 Study of Gefitinib With or Without Pemetrexed as First line Treatment in Nonsquamous NSCLC With EGFR Mutation: Final Overall Survival and Biomarker Analysis // J Thorac Oncol. — 2020. — Jan. — T. 15, № 1. — C. 91 100.

15. Yang J. C., Wu Y. L., Schuler M., Sebastian M., Popat S., Yamamoto N., Zhou C., Hu C. P., O’Byrne K., Feng J., Lu S., Huang Y., Geater S. L., Lee K. Y., Tsai C. M., Gorbunova V., Hirsh V., Bennouna J., Orlov S., Mok T., Boyer M., Su W. C., Lee K. H., Kato T., Massey D., Shahidi M., Zazulina V., Sequist L. V. Afatinib versus cisplatin based chemotherapy for EGFR mutation positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials // Lancet Oncol. — 2015. — Feb. — T. 16, № 2. — C. 141 51.

16. Zhang L., Zhao H., Zhang Z., Yao W., Min X., Gu K., Yu G., Cheng C., Cui J., Miao L., Song X., Zhang L., Yuan X., Fang Y., Fu X., Hu C., Zhu X., Fan Y., Yu Q. ACTIVE: apatinib plus gefitinib versus placebo plus gefitinib as first line treatment for advanced epidermal growth factor receptor mutant (EGFRm) non small cell lung cancer (NSCLC): a multicentered, randomized, double blind, placebo controlled phase III trial (CTONG1706). Presented at: 2020 ESMO Congress; September 19 21, 2020; virtual. Abstract LBA50.